Comparative Pharmacology
Head-to-head clinical analysis: NAFCILLIN SODIUM versus TRIMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFCILLIN SODIUM versus TRIMOX.
NAFCILLIN SODIUM vs TRIMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours depending on infection severity.
None Documented
None Documented
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
Terminal elimination half-life: 1-1.5 hours (normal renal function); in renal impairment (CrCl <10 mL/min), extends to 6-20 hours, requiring dose adjustment.
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Renal: 50-85% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minimal, <5%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic